For more information or confidential assistance
se habla español


Androgel Lawsuits Identified for Bellwether Trial Pool

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

Report Highlights Diabetic Ketoacidosis Risk Factors for SGLT2 Inhibitor Patients

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

Zofran Lawsuit Claims Drug Caused Baby’s Atrial Septal Defect

pregnant woman wearing white in profile
Drug maker GlaxoSmithKline (GSK) is named defendant in a Zofran lawsuit alleging the drug carries a disproportionate risk of causing congenital birth defects when taken by pregnant women. The complaint was filed by a minor plaintiff and her parents in the United States District Court for the Northern District of... Read more »

Testosterone Injury Lawsuits Approach 2,000 Mark

The number of product liability complaints regarding testosterone replacement therapy continues to skyrocket, with allegations that the products caused heart attacks, stroke, and debilitating blood clot injuries. Men who took supplements such as Axiron, Testim and Androgel are seeking fair compensation and justice through the legal system, based on counts... Read more »

Zofran Lawsuit Alleges Link to Clubfoot

GlaxoSmithKline is facing a Zofran lawsuit that contends the off-label morning sickness drug is dangerous to the developing fetus. The complaint is just one among many others containing similar allegations regarding the anti-nausea medication and birth defects. The case, filed in the US District Court for the District of New Jersey, demands... Read more »

Australian Health Regulators Question Benefit of Xarelto Monitoring

Foreign regulators in Australia completed a review of a new class or oral anticoagulants – Xarelto, Pradaxa and Eliquis – finding little evidence to support the benefits of routine blood monitoring in patients. Prescriptions for these blood thinning medications have skyrocketed in recent years, primarily because of their dosing convenience, allowing... Read more »

New Class of Diabetes Drugs Subject of FDA Warning

Less than two weeks ago, the FDA released an important drug safety communication regarding a new class of diabetes drugs, including those marketed under the brand names Invokana, Farxiga and Jardiance. Health regulators caution that diabetic patients taking this class of sodium-glucose cotransporter-2 (SGLT2) inhibitors may be at risk for... Read more »

Granuflo Wrongful Death Claim Joins MDL 2428

Accusations leveled in a recent Granuflo lawsuit state that plaintiff William Cox died as an alleged result of his exposure to the dialysate. The short form complaint was filed directly into the Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation on April 22, 2015. Debra Phelps is the anticipated personal representative of... Read more »

JPML Denies Motion to Centralize Testofen Lawsuits

The Judicial Panel on Multidistrict Litigation (JPML) is a panel of federal judges that is authorized to determine whether civil actions pending in district courts should be moved to one federal court for consolidated pretrial proceedings. This centralization of cases is meant to help conserve judicial resources, reduce chance of duplicative... Read more »

Research Misconduct Involving Xarelto Goes Unreported

xarelto pill bottle
JAMA Internal Medicine recently published a study by Charles Seife that highlights a profound flaw in how consumers obtain information about clinical drug trials. According to the New York University professor, only 4 percent of questionable practices or violations discovered by health regulators during pharmaceutical trials ever reaches the public.... Read more »